![](/img/cover-not-exists.png)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Baeten, Dominique, Østergaard, Mikkel, Wei, James Cheng-Chung, Sieper, Joachim, Järvinen, Pentti, Tam, Lai-Shan, Salvarani, Carlo, Kim, Tae-Hwan, Solinger, Alan, Datsenko, Yakov, Pamulapati, ChandraseVolume:
77
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2018-213328
Date:
September, 2018
File:
PDF, 1.27 MB
english, 2018